- Home
- LRFC vs ATNM Comparison
LRFC vs ATNM Comparison
Compare LRFC & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRFC
- ATNM
- Stock Information
- Founded
- LRFC 2013
- ATNM 2000
- Country
- LRFC United States
- ATNM United States
- Employees
- LRFC N/A
- ATNM N/A
- Industry
- LRFC Finance: Consumer Services
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- LRFC Finance
- ATNM Health Care
- Exchange
- LRFC Nasdaq
- ATNM Nasdaq
- Market Cap
- LRFC 68.2M
- ATNM 56.5M
- IPO Year
- LRFC 2013
- ATNM N/A
- Fundamental
- Price
- LRFC $23.92
- ATNM $1.40
- Analyst Decision
- LRFC
- ATNM Strong Buy
- Analyst Count
- LRFC 0
- ATNM 4
- Target Price
- LRFC N/A
- ATNM $8.75
- AVG Volume (30 Days)
- LRFC 6.4K
- ATNM 342.1K
- Earning Date
- LRFC 03-12-2025
- ATNM 11-14-2024
- Dividend Yield
- LRFC 5.60%
- ATNM N/A
- EPS Growth
- LRFC N/A
- ATNM N/A
- EPS
- LRFC N/A
- ATNM N/A
- Revenue
- LRFC $19,936,000.00
- ATNM $81,000.00
- Revenue This Year
- LRFC $3.63
- ATNM $138.42
- Revenue Next Year
- LRFC N/A
- ATNM $19,479.88
- P/E Ratio
- LRFC N/A
- ATNM N/A
- Revenue Growth
- LRFC N/A
- ATNM N/A
- 52 Week Low
- LRFC $20.65
- ATNM $1.10
- 52 Week High
- LRFC $26.00
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- LRFC 38.64
- ATNM 56.03
- Support Level
- LRFC $23.78
- ATNM $1.18
- Resistance Level
- LRFC $24.80
- ATNM $1.48
- Average True Range (ATR)
- LRFC 0.51
- ATNM 0.10
- MACD
- LRFC -0.07
- ATNM 0.01
- Stochastic Oscillator
- LRFC 20.59
- ATNM 75.00
About LRFC Logan Ridge Finance Corporation
Logan Ridge Finance Corp an externally managed non-diversified closed-end management investment company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company offers customized financing to business owners, management teams, and financial sponsors for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion, and other growth initiatives.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.